David S. Morris, MD, FACS, Benjamin Garmezy, MD, and John G. Phillips, MD, MPH, examine PSMA PET, molecular testing, and treatment intensification in metastatic hormone-sensitive prostate cancer.
Read More
E. David Crawford, MD, and Daniel P. Petrylak, MD, discuss PARP inhibition, TALAPRO-3, HRR alterations, and genomic testing in metastatic prostate cancer.
Read More
Dr. Hanan Goldberg reviews current evidence supporting metastasis-directed therapy for oligometastatic prostate cancer while discussing systemic therapy, PSMA PET, patient selection, and the unanswered questions that continue to shape clinical practice.
Read More
Dr. Scott B. Sellinger reviews PTEN deficiency, AKT signaling, and CAPItello-281 findings in metastatic hormone-sensitive prostate cancer.
Read More
Dr. Scott B. Sellinger discusses PTEN testing, patient selection, and the clinical implications of CAPItello-281 in metastatic hormone-sensitive prostate cancer.
Read More